Ligands and receptors of the TNF superfamily are decreased in major depression and during early antidepressant therapy.


Journal

Journal of psychiatric research
ISSN: 1879-1379
Titre abrégé: J Psychiatr Res
Pays: England
ID NLM: 0376331

Informations de publication

Date de publication:
12 2019
Historique:
received: 10 08 2018
revised: 27 08 2019
accepted: 23 09 2019
pubmed: 18 10 2019
medline: 15 9 2020
entrez: 18 10 2019
Statut: ppublish

Résumé

The up-regulation of pro-inflammatory agents, amongst them tumor necrosis factor (TNF), may represent low-grade inflammation in major depression. To further elucidate inflammatory mechanisms related to TNF in depression, the aim of the current study was to investigate the involvement of ligands and receptors of the TNF/TNF-receptor-superfamily yet un- or little explored in major depression. Serum levels of ligands (TNF, TNF-related weak inducer of apoptosis [TWEAK], B-cell activating factor [BAFF], tumor necrosis factor superfamily member 14 [TNFSF14; LIGHT], A proliferation-inducing ligand [APRIL]) and receptor molecules (TNF receptor superfamily member 8 [TNFRSF8; sCD30], soluble TNF receptor type 1 [sTNFR1] and type 2 [sTNFR2]) of the TNF/TNF-receptor-superfamily were measured in 50 unmedicated patients suffering from major depression and 48 healthy controls and were reassessed in 37 of the depressed patients two weeks after the initiation of antidepressive treatment. In comparison to the healthy controls, the interrelated serum levels of TWEAK, BAFF, TNFSF8, sTNFR1 and sTNFR2 were reduced both in the unmedicated and medicated depressed patients. Serum levels of BAFF and TNF significantly increased during the initiation of antidepressive treatment. In the combined sample of unmedicated depressed and healthy controls, but not the separate groups, scores of the BDI-II inversely correlated with levels of TWEAK, BAFF, sTNFR1, sTNFR2 and TNFSF8. The current findings give evidence for a role of the TNF/TNF-receptor-superfamily in the pathophysiology of major depression that may involve reduced tissue regeneration and neurogenesis rather than an acceleration of pro-inflammatory pathways.

Sections du résumé

BACKGROUND
The up-regulation of pro-inflammatory agents, amongst them tumor necrosis factor (TNF), may represent low-grade inflammation in major depression. To further elucidate inflammatory mechanisms related to TNF in depression, the aim of the current study was to investigate the involvement of ligands and receptors of the TNF/TNF-receptor-superfamily yet un- or little explored in major depression.
METHODS
Serum levels of ligands (TNF, TNF-related weak inducer of apoptosis [TWEAK], B-cell activating factor [BAFF], tumor necrosis factor superfamily member 14 [TNFSF14; LIGHT], A proliferation-inducing ligand [APRIL]) and receptor molecules (TNF receptor superfamily member 8 [TNFRSF8; sCD30], soluble TNF receptor type 1 [sTNFR1] and type 2 [sTNFR2]) of the TNF/TNF-receptor-superfamily were measured in 50 unmedicated patients suffering from major depression and 48 healthy controls and were reassessed in 37 of the depressed patients two weeks after the initiation of antidepressive treatment.
RESULTS
In comparison to the healthy controls, the interrelated serum levels of TWEAK, BAFF, TNFSF8, sTNFR1 and sTNFR2 were reduced both in the unmedicated and medicated depressed patients. Serum levels of BAFF and TNF significantly increased during the initiation of antidepressive treatment. In the combined sample of unmedicated depressed and healthy controls, but not the separate groups, scores of the BDI-II inversely correlated with levels of TWEAK, BAFF, sTNFR1, sTNFR2 and TNFSF8.
CONCLUSION
The current findings give evidence for a role of the TNF/TNF-receptor-superfamily in the pathophysiology of major depression that may involve reduced tissue regeneration and neurogenesis rather than an acceleration of pro-inflammatory pathways.

Identifiants

pubmed: 31622870
pii: S0022-3956(18)30705-2
doi: 10.1016/j.jpsychires.2019.09.010
pii:
doi:

Substances chimiques

Antidepressive Agents 0
Ligands 0
Receptors, Tumor Necrosis Factor 0
Tumor Necrosis Factor-alpha 0
Tumor Necrosis Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

116-121

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Frank M Schmidt (FM)

Department of Psychiatry and Psychotherapy, University Hospital Leipzig, Semmelweisstr. 10, D-04103, Leipzig, Germany. Electronic address: f.schmidt@medizin.uni-leipzig.de.

Jenny Koch (J)

Department of Psychiatry and Psychotherapy, University Hospital Leipzig, Semmelweisstr. 10, D-04103, Leipzig, Germany.

Claudia Nowak (C)

Department of Psychiatry and Psychotherapy, University Hospital Leipzig, Semmelweisstr. 10, D-04103, Leipzig, Germany.

Lesca M Holdt (LM)

Institute of Laboratory Medicine, University Hospital Ludwig-Maximilian-University Munich, Munich, Germany.

Daniel Teupser (D)

Institute of Laboratory Medicine, University Hospital Ludwig-Maximilian-University Munich, Munich, Germany.

Ulrich Hegerl (U)

Johann Christian Senckenberg Distinguished Professorship, Department of Psychiatry, Psychosomatics, and Psychotherapy, Goethe-Universität Frankfurt, Germany.

Hubertus Himmerich (H)

Department of Psychological Medicine, King's College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH